U.S. patent application number 11/978961 was filed with the patent office on 2009-06-11 for indexed library of cells containing genomic modifications and methods of making and utilizing the same.
This patent application is currently assigned to Lexicon Pharmaceuticals, Inc.. Invention is credited to Allan Bradley, Glenn A. Friedrich, Arthur T. Sands, Brian Zambrowicz.
Application Number | 20090149336 11/978961 |
Document ID | / |
Family ID | 27419091 |
Filed Date | 2009-06-11 |
United States Patent
Application |
20090149336 |
Kind Code |
A1 |
Zambrowicz; Brian ; et
al. |
June 11, 2009 |
Indexed library of cells containing genomic modifications and
methods of making and utilizing the same
Abstract
Methods and vectors (both DNA and retroviral) are provided for
the construction of a Library of mutated cells. The Library will
preferably contain mutations in essentially all genes present in
the genome of the cells. The nature of the Library and the vectors
allow for methods of screening for mutations in specific genes, and
for gathering nucleotide sequence data from each mutated gene to
provide a database of tagged gene sequences. Such a database
provides a means to access the individual mutant cell clones
contained in the Library. The invention includes the described
Library, methods of making the same, and vectors used to construct
the Library. Methods are also provided for accessing individual
parts of the Library either by sequence or by pooling and
screening. The invention also provides for the generation of
non-human transgenic animals which are mutant for specific genes as
isolated and generated from the cells of the Library.
Inventors: |
Zambrowicz; Brian; (The
Woodlands, TX) ; Friedrich; Glenn A.; (The Woodlands,
TX) ; Bradley; Allan; (Houston, TX) ; Sands;
Arthur T.; (The Woodlands, TX) |
Correspondence
Address: |
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER;LLP
901 NEW YORK AVENUE, NW
WASHINGTON
DC
20001-4413
US
|
Assignee: |
Lexicon Pharmaceuticals,
Inc.
|
Family ID: |
27419091 |
Appl. No.: |
11/978961 |
Filed: |
October 29, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10917273 |
Aug 11, 2004 |
7332338 |
|
|
11978961 |
|
|
|
|
09570923 |
May 15, 2000 |
|
|
|
10917273 |
|
|
|
|
08942806 |
Oct 2, 1997 |
6207371 |
|
|
09570923 |
|
|
|
|
08726867 |
Oct 4, 1996 |
6136566 |
|
|
08942806 |
|
|
|
|
Current U.S.
Class: |
506/9 |
Current CPC
Class: |
A01K 2217/075 20130101;
C12N 15/1082 20130101; C12N 2740/10043 20130101; C12N 15/1051
20130101; C12N 15/1034 20130101; C12N 15/86 20130101; C12N 2840/44
20130101; C12N 15/85 20130101; C12N 2800/60 20130101; C12N 2840/203
20130101; C12N 15/102 20130101 |
Class at
Publication: |
506/9 |
International
Class: |
C40B 30/04 20060101
C40B030/04 |
Claims
1-28. (canceled)
29. A method of identifying an ES cell clone having a mutation in a
selected gene from a collection of ES cell clones having
nonspecific mutations in the genome, comprising: a) providing at
least two pools of ES cell clones having nonspecific mutations in
the genome, wherein each pool comprises at least two samples
wherein each sample comprises at least 1 ES cell clone, and wherein
each pool comprises at least 16 ES cell clones; b) screening the at
least two pools of ES cell clones to identify one or more pools
comprising an ES cell clone having a mutation in the selected gene;
and c) identifying an ES cell clone having a mutation in the
selected gene.
30. The method of claim 29, wherein the screening comprises a
method selected from PCR and hybridization.
31. The method of claim 29, wherein identifying one or more pools
comprising an ES cell clone having a mutation in the selected gene
results in identifying an ES cell clone having a mutation in the
selected gene.
32. The method of claim 29, wherein each sample is at least one
well of a multiwell plate.
33. The method of claim 32, wherein identifying an ES cell clone
having a mutation in the selected gene comprises identifying a well
of a multiwell plate based on which pools of ES cell clones
comprise an ES cell clone having a mutation in the selected
gene.
34. The method of claim 29, wherein identifying an ES cell clone
having a mutation in the selected gene comprises separating at
least one sample comprising a plurality of ES cell clones having
mutations in the genome into individual ES cell clones and
screening the individual ES cell clones to identify the ES cell
clone having a mutation in the selected gene.
35. The method of claim 34, wherein the screening the individual ES
cell clones comprises a method selected from PCR and
hybridization.
36. The method of claim 29, wherein identifying an ES cell clone
having a mutation in the selected gene comprises: a) identifying at
least one sample comprising a plurality of ES cell clones having
mutations in the genome, wherein the plurality includes an ES cell
clone having a mutation in the selected gene, based on which pools
of ES cell clones comprise an ES cell clone having a mutation in
the selected gene; b) separating the plurality of ES cell clones of
the sample into individual ES cell clones; and c) screening the
individual ES cell clones to identify the ES cell clone having a
mutation in the selected gene.
37. The method of claim 36, wherein the at least one sample is at
least one well of a multi-well plate.
38. The method of claim 36, wherein the at least one sample
comprises at least 50 ES cell clones having mutations in the
genome.
39. The method of claim 36, wherein the screening comprises a
method selected from PCR and hybridization.
40. The method of claim 29, wherein identifying an ES cell clone
having a mutation in the selected gene comprises: a) identifying at
least one sample comprising a plurality of ES cell clones having
mutations in the genome, wherein the plurality includes an ES cell
clone having a mutation in the selected gene, based on which pools
of ES cell clones comprise an ES cell clone having a mutation in
the selected gene; b) separating the plurality of ES cell clones of
the sample into individual ES cell clones; c) forming at least two
pools of individual ES cell clones; d) screening the at least two
pools of individual ES cell clones to identify one or more pools of
individual ES cell clones that comprise an ES cell clone having a
mutation in the selected gene; and e) identifying an ES cell clone
having a mutation in the selected gene based on which pools of
individual ES cell clones comprise an ES cell clone having a
mutation in the selected gene.
41. The method of claim 40, wherein the at least one sample is at
least one well of a multi-well plate.
42. The method of claim 40, wherein the sample comprises at least
50 ES cell clones having mutations in the genome.
43. The method of claim 40, wherein the screening comprises a
method selected from PCR and hybridization.
44. The method of claim 29, wherein each pool of ES cell clones in
(a) comprises at least 24 ES cell clones.
45. The method of claim 29, wherein each pool of ES cell clones in
(a) comprises at least 50 ES cell clones.
46. The method of claim 29, wherein each pool of ES cell clones in
(a) comprises at least 1200 ES cell clones.
47. The method of claim 29, wherein at least one pool of ES cell
clones in (a) is made by pooling the wells of at least one column
of at least one 96-well plate.
48. The method of claim 29, wherein at least one pool of ES cell
clones in (a) is made by pooling the wells of at least one row of
at least one 96-well plate.
49. The method of claim 29, wherein at least one pool of ES cell
clones in (a) is made by pooling all of the wells of at least one
96-well plate.
50. The method of claim 29, wherein each ES cell clone having a
nonspecific mutation in the genome comprises a vector inserted
nonspecifically into its genome.
51. The method of claim 50, wherein the vector is a viral
vector.
52. The method of claim 51, wherein the vector is a retroviral
vector.
53. The method of claim 50, wherein the vector is a gene trapping
vector.
Description
[0001] The present application is a continuation-in-part of U.S.
application Ser. No. 08/726,867, filed Oct. 4, 1996, and
08/728,963, filed Oct. 11, 1996. The application also claims
priority to U.S. application Ser. No. 08/907,598, filed Aug. 8,
1997. The disclosures of the above applications are herein
incorporated by reference.
1.0. FIELD OF THE INVENTION
[0002] The invention relates to an indexed library of genetically
altered cells and methods of organizing the cells into an easily
manipulated and characterized Library. The invention also relates
to methods of making the library, vectors for making insertion
mutations in genes, methods of gathering sequence information from
each member clone of the Library, and methods of isolating a
particular clone of interest from the Library.
2.0. BACKGROUND OF THE INVENTION
[0003] The general technologies of targeting mutations into the
genome of cells, and the process of generating mouse lines from
genetically altered embryonic stem (ES) cells with specific genetic
lesions are well known (Bradley, 1991, Cur. Opin. Biotech.
2:823-829). A random method of generating genetic lesions in cells
(called gene, or promoter, trapping) has been developed in parallel
with the targeted methods of genetic mutation (Allen et al., 1988
Nature 333(6176):852-855; Brenner et al., 1989, Proc. Natl. Acad.
Sci. U.S.A. 86(14):5517-5521; Chang et al., 1993, Virology
193(2):737-747; Friedrich and Soriano, 1993, Insertional
mutagenesis by retroviruses and promoter traps in embryonic stem
cells, p. 681-701. In Methods Enzymol., vol. 225., P. M. Wassarman
and M. L. DePamphilis (ed.), Academic Press, Inc., San Diego;
Friedrich and Soriano, 1991, Genes Dev. 5(9):1513-1523; Gossler et
al., 1989, Science 244(4903):463-465; Kerr et al., 1989, Cold
Spring Harb. Symp. Quant. Biol. 2:767-776; Reddy et al., 1991, J.
Virol. 65(3):1507-1515; Reddy et al., 1992, Proc. Natl. Acad. Sci.
U.S.A. 89(15):6721-6725; Skarnes et al., 1992, Genes Dev.
6(6):903-918; von Melchner and Ruley, 1989, J. Virol.
63(8):3227-3233; Yoshida et al., 1995, Transgen. Res. 4:277-287).
Gene trapping provides a means to create a collection of random
mutations by inserting fragments of DNA into transcribed genes.
Insertions into transcribed genes are selected over the background
of total insertions since the mutagenic DNA encodes an antibiotic
resistance gene or some other selectable marker. The selectable
marker lacks its own promoter and enhancer and must be expressed by
the endogenous sequences that flank the marker after it has
integrated. Using this approach, transcription of the selectable
marker is activated and the cell gene is concurrently mutated. This
type of strict selection makes it possible to easily isolate
thousands of ES cell colonies, each with a unique mutagenic
insertion.
[0004] Collecting mutants on a large-scale has been a powerful
genetic technique commonly used for organisms which are more
amenable to such analysis than mammals. These organisms, such as
Drosophila melanogastor, yeast Saccharomyces cerevisiae, and plants
such as Arabadopsis thalia are small, have short generation times
and small genomes (Bellen et al., 1989, Genes Dev. 3(9):1288-1300;
Bier et al., 1989, Genes Dev. 3(9):1273-1287; Hope, 1991, Develop.
113(2):399-408. These features allow an investigator to rear many
thousands or millions of different mutant strains without requiring
unmanageable resources. However, these type of organisms have only
limited value in the study of biology relevant to human physiology
and health. It is therefore important to have the power of
large-scale genetic analysis available for the study of a mammalian
species that can aid in the study of human disease. Given that the
entire human genome is presently being sequenced, the comprehensive
genetic analysis of a related mammalian species will provide a
means to determine the function of genes cloned from the human
genome. At present, rodents, and particularly mice, provide the
best model for genetic manipulation and analysis of mammalian
physiology.
[0005] Gene trapping has been used as an analytical tool to
identify genes and regulatory regions in a variety of animal cell
types. One system that has proved particularly useful is based on
the use of ROSA (reverse orientation splice acceptor) retroviral
vectors (Friedrich and Soriano, 1991 and 1993).
[0006] The ROSA system can generate mutations that result in a
detectable homozygous phenotype with a high frequency. About 50% of
all the insertions caused embryonic lethality. The specifically
mutated genes may easily be cloned since the gene trapping event
produces a fusion transcript. This fusion transcript has trapped
exon sequences appended to the sequences of the selectable marker
allowing the latter to be used as a tag in polymerase chain
reaction (PCR)-based protocols, or by simple cDNA cloning. Examples
of genes isolated by these methods include a transcription factor
related to human TEF-1 (transcription enhancer factor-1) which is
required in the development of the heart (Chen et al., 1994, Genes
Devel. 8:2293-2301. Another (spock), is distantly related to yeast
genes encoding secretion proteins and is important during
gastrulation.
[0007] The above experiments have established that the ROSA system
is an effective analytical tool for genetic analysis in mammals.
However, the structure of many ROSA vectors selects for the
"trapping" of 5' exons which, in many cases, do not encode
proteins. Such a result is adequate where one wishes to identify
and eventually clone control (i.e., promoter or enhancer)
sequences, but is not optimal where the generation of
insertion-inactivated null mutations is desired, and relevant
coding sequence is needed. Thus, the construction of large-scale
mutant (preferably null mutant) libraries requires the use of
vectors that have been designed to select for insertion events that
have occurred within the coding region of the mutated genes as well
as vectors that are not limited to detecting insertions into
expressed genes.
3.0. SUMMARY OF THE INVENTION
[0008] An object of the present invention is to provide a set of
genetically altered cells (the `Library`). The genetic alterations
are of sufficient randomness and frequency such that the combined
population of cells in the Library represent mutations in
essentially every gene found in the cell's genome. The Library is
used as a source for obtaining specifically mutated cells, cell
lines derived from the individually mutated cells, and cells for
use in the production of transgenic non-human animals.
[0009] A further object is to provide the vectors, both DNA and
retroviral based, that may be used to generate the Library.
Typically, at least two distinct vector designs will be used in
order to mutate genes that are actively expressed in the target
cell, and genes that are not expressed in the target cell.
Combining the mutant cells obtained using both types of vectors
best ensures that the Library provides a comprehensive set of gene
mutations.
[0010] A particularly useful vector class contemplated by the
present invention includes a vector for inserting foreign exons
into animal cell transcripts that comprises a selectable marker, a
promoter element operatively positioned 5' to the selectable
marker, a splice donor site operatively positioned 3' to the
selectable marker, and a second mutagenic foreign polynucleotide
sequence located upstream from the promoter element that disrupts,
or otherwise "poisons", the splicing or read-through expression of
the endogenous cellular transcript. Typically, the mutagenic
foreign polynucleotide sequence may incorporate a polyadenylation
(pA) site, a nested set of stop codons in each of the three reading
frames, splice acceptor and splice donor sequences in operable
combination, a mutagenic exon, or any mixture of mutagenic features
that effectively prevent the expression of the cellular gene. For
example, a polyadenylation sequence may be incorporated in addition
to or in lieu of the splice donor sequence. A preferred
organization for the mutagenic polynucleotide sequence comprises a
polyadenylation site positioned upstream from a selectable marker
which is in turn located upstream from a splice acceptor sequence.
Preferably, such a vector does not comprise a transcription
terminator or polyadenylation site operatively positioned relative
to the coding region of the selectable marker, and shall not
comprise a splice acceptor site operatively positioned between the
promoter element and the initiation codon of said selectable
marker.
[0011] An additional vector contemplated by the present invention
is designed to replace the normal 3' end of an animal cell
transcript with a foreign exon. Such a vector shall generally be
engineered to comprise a selectable marker, a splice acceptor site
operatively positioned upstream (5') from the initiation codon of
the selectable marker, and a polyadenylation site operatively
positioned downstream (3') from the termination codon (3' end) of
the selectable marker. Preferably, the vector will not comprise a
promoter element operatively positioned upstream from the coding
region of the selectable marker, and will not comprise a splice
donor sequence operatively positioned between the 3' end of the
coding region of the selectable marker and the polyadenylation
site.
[0012] Yet another vector contemplated by the present invention is
a vector designed to insert a mutagenic foreign polynucleotide
sequence within an animal cell transcript (i.e., the foreign
polynucleotide sequence is flanked on both sides by endogenous
exons). As described above, the mutagenic foreign polynucleotide
sequence may be any sequence that disrupts the normal expression of
the gene into which the vector has integrated. Optionally, the
vector may additionally incorporate a selectable marker, a splice
acceptor site operatively positioned 5' to the initiation codon of
the selectable marker, a splice donor site operatively positioned
3' to said selectable marker. Preferably, this vector shall not
comprise a polyadenylation site operatively positioned 3' to the
coding region of said selectable marker, and shall not comprise a
promoter element operatively positioned 5' to the coding region of
said selectable marker.
[0013] An additional embodiment of the present invention is a
library of genetically altered cells that have been treated to
stably incorporate one or more types of the vectors described
above. The presently described library of cultured animal cells may
be made by a process comprising the steps of treating (i.e.,
infecting, transfecting, retrotransposing, or virtually any other
method of introducing polynucleotides into a cell) a population of
cells to stably integrate a vector that mediates the splicing of a
foreign exon internal to a cellular transcript, transfecting
another population of cells to stably integrate a vector that
mediates the splicing of a foreign exon 5' to an exon of a cellular
transcript, and selecting for transduced cells that express the
products encoded by the foreign exons.
[0014] Alternatively, an additional embodiment of the present
invention describes a mammalian cell library made by a method
comprising the steps of: transfecting a population of cells with a
vector capable of expressing a selectable marker in the cell only
after the vector inserts into the host genome; transfecting or
infecting a population of cells with a vector containing a
selectable marker that is substantially only expressed by cellular
control sequences (after the vector integrates into the host cells
genome); and growing the transfected cells under conditions that
select for the expression of the selectable marker.
[0015] In an additional embodiment of the present invention, the
two populations of transfected cells will be individually grown
under selective conditions, and the resulting mutated population of
cells collectively comprises a substantially comprehensive library
of mutated cells.
[0016] In an additional embodiment of the present invention, the
individual mutant cells in the library are separated and clonally
expanded. Additionally, the clonally expanded mutant cells may then
be analyzed to ascertain the DNA sequence, or partial DNA sequence
of the mutated host gene.
[0017] The presently described methods of making, organizing, and
indexing libraries of mutated animal cells are also broadly
applicable to virtually any eukaryotic cells that may be
genetically manipulated and grown in culture.
[0018] The invention provides for sequencing every gene mutated in
the Library. The resulting sequence database subsequently serves as
an index for the library. In essence, every cell line in the
Library is individually catalogued using the partial sequence
information. The resulting sequence is specific for the mutated
gene since the present methods are designed to obtain sequence
information from exons that have been spliced to the marker
sequence. Since the coverage of the mutagenesis is preferably the
entire set of genes in the genome, the resulting Library sequence
database contains sequence from essentially every gene in the cell.
From this database, a gene of interest can be identified. Once
identified, the corresponding mutant cell may be withdrawn from the
Library based on cross reference to the sequence data.
[0019] An additional embodiment of the invention provides for
methods of isolating mutations of interest from the Library. Two
methods are proposed for obtaining individual mutant cell lines
from the Library. The first provides a scheme where clones of the
cells generated using the above vectors are pooled into sets of
defined size. Using the procedure described below which utilizes
reverse transcription (RT) and polymerase chain reaction (PCR), a
cell line with a mutation in a gene whose sequence is partly or
wholly known is isolated from organized sets of these pools. A few
rounds of this screening procedure results in the isolation of the
desired individual cell line.
[0020] A second procedure involves the sequencing of regions
flanking the vector insertion sites in the various cells in the
library. The sequence database generated from these data
effectively constitutes an index of the clones in the library that
may be used to identify cells having mutations in specific
genes.
4.0. DESCRIPTION OF THE FIGURES
[0021] FIG. 1. Shows a diagrammatic representation of 5 different
vectors that are generally representative of the type of vectors
that may be used in the present invention.
[0022] FIG. 2. Shows a general strategy for identifying "trapped"
cellular sequences by PCR analysis of the cellular exons that flank
the foreign intron introduced by the VICTR 2 vector.
[0023] FIG. 3 shows a PCR based strategy for identifying tagged
genes by chromosomal location.
[0024] FIG. 4. Is a diagrammatic representation of a strategy of
identifying or indexing the specific clones in the library via PCR
analysis and sequencing of mRNA samples obtained from the cells in
the library.
[0025] FIG. 5. Is a diagrammatic representation of a method of
isolating positive clones by screening pooled mutant cell
clones.
[0026] FIG. 6. Partial nucleic acid or predicted amino acid
sequence data from 9 clones (OST1-9) isolated using the described
techniques aligned with similar sequences from previously
characterized genes.
[0027] FIG. 7. Provides a diagrammatic representation of VICTRs 3
and 20 as well as the transcripts that result after integration
into a hypothetical region of the target cell genome (i.e.,
"Wildtype Locus).
[0028] FIG. 8. Provides a representative list of a portion of the
known genes that have been identified using the disclosed methods
and technology.
5.0. DETAILED DESCRIPTION OF THE INVENTION
[0029] The present invention describes a novel indexed library
containing a substantially comprehensive set of mutations in the
host cell genome, and methods of making and using the same. The
presently described Library comprises as a set of cell clones that
each possess at least one mutation (and preferably a single
mutation) caused by the insertion of DNA that is foreign to the
cell. For the purposes of the present invention, "foreign"
polynucleotide sequences can be any sequences that are newly
introduced to a cell, do not naturally occur in the cell at the
engineered region of the chromosome, or occur in the cell but are
not organized to provide an identical function to that provided in
the engineered vector.
[0030] The particularly novel features of the Library include the
methods of construction, and indexing. To index the library, the
mutant cells of the library are clonally expanded and each mutated
gene is at least partially sequenced. The Library thus provides a
novel tool for assessing the specific function of a given gene. The
insertions cause a mutation which allow for essentially every gene
represented in the Library to be studied using genetic techniques
either in vitro or in vivo (via the generation of transgenic
animals). For the purposes of the present invention, the term
"essentially every gene" shall refer to the statistical situation
where there is generally at least about a 70 percent probability
that the genomes of cells used to construct the library
collectively contain at least one inserted vector sequence in each
gene, preferably a 85 percent probability, and more specifically at
least about a 95 percent probability as determined by a standard
Poisson distribution.
[0031] Also for the purposes of the present invention the term
"gene" shall refer to any and all discrete coding regions of the
cell's genome, as well as associated noncoding and regulatory
regions. Additionally, the term operatively positioned shall refer
to the control elements or genes that are provided with the proper
orientation and spacing to provide the desired or indicated
functions of the control elements or genes.
[0032] For the purposes of the present invention, a gene is
"expressed" when a control element in the cell mediates the
production of functional or detectable levels of mRNA encoded by
the gene, or a selectable marker inserted therein. A gene is not
expressed where the control element in the cell is absent, has been
inactivated, or does not mediate the production of functional or
detectable levels of mRNA encoded by the gene, or a selectable
marker inserted therein.
5.1. Vectors Used to Build the Library
[0033] A number of investigators have developed gene trapping
vectors and procedures for use in mouse and other cells (Allen et
al., 1988; Bellen et al., 1989, Genes Dev. 3(9):1288-1300; Bier et
al., 1989, Genes Dev. 3(9):1273-1287; Bonnerot et al., 1992, J.
Virol. 66(8):4982-4991; Brenner et al., 1989; Chang et al., 1993;
Friedrich and Soriano, 1993; Friedrich and Soriano, 1991; Goff,
1987, Methods Enzymol. 152:469-481; Gossler et al.; Hope, 1991;
Kerr et al., 1.98.9; Reddy et al., 1991; Reddy et al., 1992;
Skarnes et al., 1992; von Melchner and Ruley; Yoshida et al.,
1995). The gene trapping system described in the present invention
is based on significant improvements to the published SA (splice
acceptor) DNA vectors and the ROSA (reverse orientation, splice
acceptor) retroviral vectors (Chen et al., 1994; Friedrich and
Soriano, 1991 and 1993). The presently described vectors also use a
selectable marker called .beta.geo. This gene encodes a protein
which is a fusion between the .beta.-galactosidase and neomycin
phosphotransferase proteins. The presently described vectors place
a splice acceptor sequence upstream from the .beta.geo gene and a
poly-adenylation signal sequence downstream from the marker. The
marker is integrated after transfection by, for example,
electroporation (DNA vectors), or retroviral infection, and gene
trap events are selected based on resistance to G418 resulting from
activation of .beta.geo expression by splicing from the endogenous
gene into the ROSA splice acceptor. This type of integration
disrupts the transcription unit and preferably results in a null
mutation at the locus.
[0034] Although gene trapping has proven a useful analytical tool,
the present invention contemplates gene trapping on a large scale.
The vectors utilized in the present invention have been engineered
to overcome the shortcomings of the early gene trap vector designs,
and to facilitate procedures allowing high throughput. In addition,
procedures are described that allow the rapid and facile
acquisition of sequence information from each trapped cDNA which
may be adapted to allow complete automation. These latter
procedures are also designed for flexibility so that additional
molecular information can easily be obtained subsequently. The
present invention therefore incorporates gene trapping into a
larger and unique tool. A specially organized set of gene trap
clones that provide a novel and powerful new tool of genetic
analysis.
[0035] The presently described vectors are superficially similar to
the ROSA family of vectors, but constitute significant improvements
and provide for additional features that are useful in the
construction and indexing of the Library. Typically, gene trapping
vectors are designed to detect insertions into transcribed gene
regions within the genome. They generally consist of a selectable
marker whose normal expression is handicapped by exclusion of some
element required for proper transcription. When the vector
integrates into the genome, and acquires the necessary element by
juxtaposition, expression of the selectable marker is activated.
When such activation occurs, the cell can survive when grown in the
appropriate selective medium which allows for the subsequent
isolation and characterization of the trapped gene. Integration of
the gene trap generally causes the gene at the site of integration
to be mutated.
[0036] Some gene trapping vectors have a splice acceptor preceding
a selectable marker and a poly-adenylation signal following the
selectable marker, and the selectable marker gene has its own
initiator ATG codon. Using this arrangement, the fusion transcripts
produced after integration generally only comprise exons 5' to the
insertion site to the known marker sequences. Where the vector has
inserted into the 5' region of the gene, it is often the case that
the only exon 5' to the vector is a non-coding exon. Accordingly,
the sequences obtained from such fusions do not provide the desired
sequence information about the relevant gene products. This is
because untranslated sequences are generally less well conserved
than coding sequences.
[0037] To compensate for the short-comings of earlier vectors, the
vectors of the present invention have been designed so that 3'
exons are appended to the fusion transcript by replacing the
poly-adenylation and transcription termination signals of earlier
ROSA vectors with a splice donor (SD) sequence. Consequently
transcription and splicing generally results in a fusion between
all or most of the endogenous transcript and the selectable marker
exon, for example .beta.geo, neomycin (neo) or puromycin (puro).
The exon sequences immediately 3' to the selectable marker exon may
then be sequenced and used to establish a database of expressed
sequence tags. The presently described procedures will typically
provide approximately 200 nucleotides of sequence, or more. These
sequences will generally be coding and therefore informative. The
prediction that the sequence obtained will be from coding region is
based on two factors. First, gene trap vectors are generally found
near the 5' end of the gene immediately after untranslated exons
because the method selects for integration events that place the
initiator ATG of the selectable marker as the first encountered,
and thus used, for translation. Second, mammalian transcripts have
short 5' untranslated regions (UTRs) which are typically between 50
and 150 nucleotides in length.
[0038] The obtained sequence information also provides a ready
source of probes that may be used to isolate the full-length gene
or cDNA from the host cell, or as heterologous probes for the
isolation of homologous genes in other species.
[0039] Internal exons in mammalian transcripts are generally quite
small, on the average 137 bases with few over 300 bases.
Consequently, a large internal exon may be spliced less
efficiently. Thus, the presently described vectors have been
designed to sandwich relatively small selectable markers (for
example: neo, .about.800 bases, or a smaller drug resistance gene
such as puro, .about.600 bases) between the requisite splicing
elements to produce relatively small exons. Exons of this size are
more typical of mammalian exons and do not present undue problems
for the splicing machinery of the cell. Such a design consideration
is novel to the presently disclosed gene trapping vectors.
Accordingly, an additional embodiment of the claimed vectors is
that the respective splice acceptor and splice donor sites are
engineered such that they are operatively positioned close to the
ends of the selectable marker coding region (the region spanning
from the initiation codon to the termination codon). Generally, the
splice acceptor or splice donor sequences shall appear within about
80 bases from the nearest end of the selectable marker coding
region, preferably within about 50 bases from the nearest end of
the coding region, more preferably within about 30 bases from the
nearest end of the coding regions and specifically within about 20
bases of the nearest end of the selectable marker coding
region.
[0040] The new vectors are represented in retroviral form in FIG.
1. They are used by infecting target cells with retroviral
particles such that the proviruses shown in the schematic can be
found in the genome of the target. These vectors are called VICTR
which is an acronym for "viral constructs for trapping".
[0041] The presently described retroviral vectors may be used in
conjunction with retroviral packaging cell lines such as those
described in U.S. Pat. No. 5,449,614 ("'614 patent") issued Sep.
12, 1995, herein incorporated by reference. Where non-mouse animal
cells are to be used as targets for generating the described
libraries, packaging cells producing retrovirus with amphotropic
envelopes will generally be employed to allow infection of the host
cells.
[0042] The mutagenic gene trap DNA may also be introduced into the
target cell genome by various transfection techniques which are
familiar to those skilled in the art such as electroporation,
lipofection, calcium phosphate precipitation, infection,
retrotransposition, and the like. Examples of such techniques may
be found in Sambrook et al. (1989) Molecular Cloning Vols. I-III,
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., and
Current Protocols in Molecular Biology (1989) John Wiley &
Sons, all Vols. and periodic updates thereof, herein incorporated
by reference. The transfected versions of the retroviral vectors
are typically plasmid DNA molecules containing DNA cassettes
comprising the described features between the retroviral LTRs.
[0043] The vectors VICTR 1 and 2 (FIG. 1) are designed to trap
genes that are transcribed in the target cell. To trap genes that
are not expressed in the target cell, gene trap vectors such as
VICTR 3, 4 and 5 (described below) are provided. These vectors have
been engineered to contain a promoter element capable of initiating
transcription in virtually any cell type which is used to
transcribe the coding sequence of the selectable marker. However,
in order to get proper translation of the marker product, and thus
render the cell resistant to the selective antibiotic, a
polyadenylation signal and a transcription termination sequence
must be provided. Vectors VICTR 3 through 5 are constructed such
that an effective polyadenylation signal can only be provided by
splicing with an externally provided downstream exon that contains
a poly-adenylation site. Therefore, since the selectable marker
coding region ends only in a splice donor sequence, these vectors
must be integrated into a gene in order to be properly expressed.
In essence, these vectors append the foreign exon encoding the
marker to the 5' end of an endogenous transcript. These events will
tag genes and create mutations that are used to make clones that
will become part of the Library.
[0044] With the above design considerations, the VICTR series of
vectors, or similarly designed and constructed vectors, have the
following features. VICTR 1 is a terminal exon gene trap. VICTR 1
does not contain a control region that effectively mediates the
expression of the selectable marker gene. Instead, the coding
region of the selectable-marker contained in VICTR 1, in this case
encoding puromycin resistance (but which can be any selectable
marker functional in the target cell type), is preceded by a splice
acceptor sequence and followed by a polyadenylation addition signal
sequence. The coding region of the puro gene has an initiator ATG
which is downstream and adjacent to a region of sequence that is
most favorable for translation initiation in eukaryotic cells--the
so called Kozak consensus sequence (Kozak, 1989, J. Cell, Biol.
108(2):229-241). With a Kozak sequence and an initiator ATG, the
puro gene in VICTR 1 is activated by integrating into the intron of
an active gene, and the resulting fusion transcript is translated
beginning at the puromycin initiation (ATG/AUG) codon. However,
terminal gene trap vectors need not incorporate an initiator ATG
codon. In such cases, the gene trap event requires splicing and the
translation of a fusion protein that is functional for the
selectable marker activity. The inserted puromycin coding sequence
must therefore be translated in the same frame as the "trapped"
gene.
[0045] The splice acceptor sequence used in VICTR 1 and other
members of the VICTR series is derived from the adenovirus major
late transcript splice site located at the intron 1/exon 2
boundary. This sequence contains a polypyrimidine stretch preceding
the AG dinucleotide which denotes the actual splice site. The
presently described vectors contemplate the use of any similarly
derived splice acceptor sequence. Preferably, the splice acceptor
site will only rarely, if ever, be involved in alternative splicing
events.
[0046] The polyadenylation signal at the end of the puro gene is
derived from the bovine growth hormone gene. Any similarly derived
polyadenylation signal sequence could be used if it contains the
canonical AATAAA and can be demonstrated to terminate transcription
and cause a polyadenylate tail to be added to the engineered coding
exons.
[0047] VICTR 2 is a modification of VICTR 1 in which the
polyadenylation signal sequence is removed and replaced by a splice
donor sequence. Like VICTR 1, VICTR 2 does not contain a control
region that effectively mediates the expression of the selectable
marker gene. Typically, the splice donor sequence to be employed in
a VICTR series vector shall be determined by reference to
established literature or by experimentation to identify which
sequences properly initiate splicing at the 5' end of introns in
the desired target cell. The specifically exemplified sequence,
AGGTAAGT, results in splicing occurring in between the two G bases.
Genes trapped by VICTR 2 splice upstream exons onto the puro exon
and downstream exons onto the end of the puro exon. Accordingly,
VICTR 2 effectively mutates gene expression by inserting a foreign
exon in-between two naturally occurring exons in a given
transcript. Again, the puro gene may or may not contain a consensus
Kozak translation initiation sequence and properly positioned
ATG-initiation codon. As discussed above, gene trapping by VICTR 1
and VICTR 2 requires that the mutated gene is expressed in the
target cell line. By incorporating a splice donor into the VICTR
traps, transcript sequences downstream from the gene trap insertion
can be determined. As described above, these sequences are
generally more informative about the gene mutated since they are
more likely to be coding sequences. This sequence information is
gathered according to the procedures described below.
[0048] VICTR 3, VICTR 4 and VICTR 5 are gene trap vectors that do
not require the cellular expression of the endogenous trapped gene.
The VICTR vectors 3 through 5 all comprise a promoter element that
ensures that transcription of the selectable marker would be found
in all cells that have taken up the gene trap DNA. This
transcription initiates from a promoter, in this case the promoter
element from the mouse phosphoglycerate kinase (PGK) gene. However,
since the constructs lack a polyadenylation signal there can be no
proper processing of the transcript and therefore no translation.
The only means to translate the selectable marker and get a
resistant cell clone is by acquiring a polyadenylation signal.
Since polyadenylation is known to be concomitant with splicing, a
splice donor is provided at the end of the selectable marker.
Therefore, the only positive gene trap events using VICTR 3 through
5 will be those that integrate into a gene's intron such that the
marker exon is spliced to downstream exons that are properly
polyadenylated. Thus genes mutated with the VICTR vectors 3 through
5 need not be expressed in the target cell, and these gene trap
vectors can mutate all genes having at least one intron. The design
of VICTR vectors 3 through 5 requires a promoter element that will
be active in the target cell type, a selectable marker and a splice
donor sequence. Although a specific promoter was used in the
specific embodiments, it should be understood that appropriate
promoters may be selected that are known to be active in a given
cell type. Typically, the considerations for selecting the splice
donor sequence are identical to those discussed for VICTR 2,
supra.
[0049] VICTR 4 differs from VICTR 3 only by the addition of a small
exon upstream from the promoter element of VICTR 4. This exon is
intended to stop normal splicing of the mutated gene. It is
possible that insertion of VICTR 3 into an intron might not be
mutagenic if the gene can still splice between exons, bypassing the
gene trap insertion. The exon in VICTR 4 is constructed from the
adenovirus splice acceptor described above and the synthetic splice
donor also described above. Stop codons are placed in all three
reading frames in the exon, which is about 100 bases long. The
stops would truncate the endogenous protein and presumably cause a
mutation.
[0050] A conceptually similar alternative design uses a terminal
exon like that engineered into VICTR 5. Instead of a splice donor,
a polyadenylation site is used to terminate transcription and
produce a truncated message. Stops in all three frames are also
provided to truncate the endogenous protein as well as the
resulting transcript.
[0051] VICTR 20 is a modified version of VICTR 3 that incorporates
a polyadenylation site 5' to the PGK promoter, the IRES.beta.geo
sequence (i.e., foreign mutagenic polynucleotide sequence) 5' to
the polyadenylation site, and a splice acceptor site 5' to the
IRES.beta.geo coding region. VICTR 20 additionally incorporates, in
operable combination, a pair of recombinase recognition sites that
flank the PGKpuroSD cassette.
[0052] All of the traps of the VICTR series are designed such that
a fusion transcript is formed with the trapped gene. For all but
VICTR 1, the fusion contains cellular exons that are located 3' to
the gene trap insertion. All of the flanking exons may be sequenced
according to the methods described in the following section. To
facilitate sequencing, specific sequences are engineered onto the
ends of the selectable marker (e.g., puromycin coding region).
Examples of such sequences include, but are not limited to unique
sequences for priming PCR, and sequences complementary to the
standard M13 forward sequencing primer. Additionally, stop codons
are added in all three reading frames to ensure that no anomalous
fusion proteins are produced. All of the unique 3' primer sequences
are followed immediately by the synthetic 9 base pair splice donor
sequence. This keeps the size of the exon comprising the selectable
marker (puro gene) at a minimum to best ensure proper splicing, and
positions the amplification and sequencing primers immediately
adjacent to the flanking "trapped" exons to be sequenced as part of
the construction of a Library database.
[0053] When any members of the VICTR series are constructed as
retroviruses, the direction of transcription of the selectable
marker is opposite to that of the direction of the normal
transcription of the retrovirus. The reason for this organization
is that the transcription elements such as the polyadenylation
signal, the splice sites and the promoter elements found in the
various members of the VICTR series interfere with the proper
transcription of the retroviral genome in the packaging cell line.
This would eliminate or significantly reduce retroviral titers. The
LTRs used in the construction of the packaging cell line are
self-inactivating. That is, the enhancer element is removed from
the 3' U3 sequences such that the proviruses resulting from
infection would not have an enhancer in either LTR. An enhancer in
the provirus may otherwise affect transcription of the mutated gene
or nearby genes.
[0054] Since a `cryptic` splice donor sequence is found in the
inverted LTRs, this splice donor sequence has been removed from the
VICTR vectors by site specific mutagenesis. It was deemed necessary
to remove this splice donor so that it would not affect the
trapping splicing events.
[0055] The present disclosure also describes vectors that
incorporate a new way to conduct positive selection. VICTR 3 and
VICTR 20 are two examples of such vectors. Both VICTR 3 and VICTR
20, contain PGKpuroSD which must splice into exons of gene that
provide a polyadenylation addition sequence in order to allow
expression of the puromycin selectable marker gene. When placed in
a targeting vector, PGKpuroSD allows for positive selection when
targeting takes place. In addition to providing positive selection,
targeted events among resistant colonies are easy to identify by
the 3' RACE protocols (see section 5.2.2., infra) used for Omnibank
production. This automated process allows for the rapid
identification of targeted events. It is important that unlike
SA.beta.geo, PGKpuroSD does not require expression of the targeted
gene in order to provide positive selection. In addition, VICTR 20
provides 2 potential positive selectable markers (puro and neo).
The use of two selectable markers, when a gene is expressed,
provides a means to increase the targeting efficiency by requiring
both selectable markers to function which is much more remote a
possibility than having one selectable marker function unless there
is a targeted event. The addition of a negative selection cassette
to these vectors would only increase their targeting
efficiency.
[0056] An additional feature that may be incorporated into the
presently described vectors includes the use of recombinase
recognition sequences. Bacteriophage P1 Cre recombinase and flp
recombinase from yeast plasmids are two examples of site-specific
DNA recombinase enzymes which cleave DNA at specific target sites
(loxP sites for cre recombinase and frt sites for flp recombinase)
and catalyze a ligation of this DNA to a second cleaved site. When
a piece of DNA is flanked by 2 loxP or frt sites (e.g., recombinase
control elements) in the same orientation, the corresponding
recombinase will cause the removal of the intervening DNA sequence.
When a piece of DNA is flanked by loxP or frt sites in an indirect
orientation, the corresponding recombinase will essentially
activate the control elements to cause the intervening DNA to be
flipped into the opposite orientation. These recombinases provide
powerful approaches for manipulating DNA in situ.
[0057] Recombinases, have important applications for gene trapping
and the production of a library of trapped genes. When constructs
containing PGKpuroSD are used to trap genes, the fusion transcript
between puromycin and sequences of the trapped gene could result in
some level of protein expression from the trapped gene if
translational reinitiation occurs. Another important issue is that
several reports suggest that the PGK promoter can affect the
expression of nearby genes. These effects may make it difficult to
determine gene function after a gene trap event since one could not
discern whether a given phenotype is associated with the
inactivation of a gene, or the transcription of nearby genes. Both
potential problems are solved by exploiting recombinase activity.
When PGKpuroSD is flanked by loxP, frt, or any other recombinase
sites in the same orientation, the addition of the corresponding
recombinase will result in the removal of PGKpuroSD. In this way,
effects caused by PGKpuroSD fusion transcripts, or the PGK
promoter, are avoided.
[0058] Accordingly, a vector that may be particularly useful for
the practice of the present invention is VICTR 20. This vector
replaces the terminal exon of VICTR 5 with a splice acceptor
located upstream from the .beta.geo gene which can be used for both
LacZ staining and antibiotic selection. The fusion gene possesses
its own initiator methionine and an internal ribosomal entry site
(IRES) for efficient translation initiation. In addition, the PGK
promoter and puromycin-splice donor sequences have been flanked by
lox P recombination sites. This allows for the ability to both
remove and introduce sequences at the integration site and is of
potential value with regard to the manipulation of regions proximal
to trapped target genes (Barinaga, Science 265:26-8, 1994). While
this particular vector includes lox P recombination sites, the
present invention is in no way limited to the use of this specific
recombination site (Akagi et al., Nucleic Acids Res 25:1766-73,
1997).
[0059] Another very important use of recombinases is to produce
mutations that can be made tissue-specific and/or inducible. In the
presently described vectors, the Sa.beta.geo or SAIRES.beta.geo
component provides the mutagenic function by "trapping" the normal
splicing from preceding exons. If the SA.beta.geo is flanked by
inverted loxP, frt, or any other recombinase sites, the addition of
the corresponding recombinase results in the flipping of the
SA.beta.geo sequence so that it no longer prevents the normal
splicing of the cellular gene into which it is integrated. To make
a gene trap tissue-specific or inducible one could produce the trap
with SA.beta.geo in the reverse orientation and then provide
recombinase activity only at the time and place where one wishes to
remove the gene function. The use of tissue-specific or inducible
recombinase constructs allows one to choose when and where one
removes, or activates, the function of the targeted gene.
[0060] One method for practicing the inducible forms of recombinase
mediated gene expression involves the use of vectors that use
inducible or tissue specific promoter/operator elements to express
the desired recombinase activity. The inducible expression elements
are preferably operatively positioned to allow the inducible
control or activation of expression of the desired recombinase
activity. Examples of such inducible promoters or control elements
include, but are not limited to, tetracycline, metallothionine,
ecdysone, and other steroid-responsive promoters, rapamycin
responsive promoters, and the like (No et al., Proc Natl Acad Sci
USA 93:3345-51, 1996; Furth et al., Proc Natl Acad Sci USA
91:9302-6, 1994). Additional control elements that can be used
include promoters requiring specific transcription factors such as
viral, particularly HIV, promoters. Vectors incorporating such
promoters would only express recombinase activity in cells that
express the necessary transcription factors.
[0061] The incorporation of recombinase sites into the gene
trapping vectors highlights the value of using the described gene
trap vectors to deliver specific DNA sequence elements throughout
the genome. Although a variety of vectors are available for placing
sequences into the genome, the presently described vectors
facilitate both the insertion of the specific elements, and the
subsequent identification of where sequence has inserted into the
cellular chromosome. Additionally, the presently described vectors
may be used to place recombinase recognition sites throughout the
genome. The recombinase recognition sites could then be used to
either remove or insert specific DNA sequences at predetermined
locations.
[0062] Moreover, the described gene trap vectors can also be used
to insert regulatory elements throughout the genome. Recent work
has identified a number of inducible or repressible systems that
function in the mouse. These include the rapamycin, tetracycline,
ecdysone, glucocorticoid, and heavy metal inducible systems. These
systems typically rely on placing DNA elements in or near a
promoter. An inducible or repressible transcription factor that can
identify and bind to the DNA element may also be engineered into
the cells. The transcription factor will specifically bind to the
DNA element in either the presence or absence of a ligand that
binds to the transcription factor and, depending on the structure
of the transcription factor, it will either induce or repress the
expression of the cellular gene into which the DNA elements have
been inserted. The ability to place these inducible or repressible
elements throughout the genome would increase the value of the
library by adding the potential to regulate the expression of the
trapped gene.
[0063] The vectors described also have important applications for
the overexpression of genes or portions of genes to select for
phenotypic effects. Currently, overexpression of cDNA libraries to
look for genes or parts of genes with specific functions is a
common practice. One example would be to overexpress genes or
portions of genes to look for expression that causes loss of
contact inhibition for cell growth as determined by growth in soft
agar. This would allow the identification of genes or portions of
genes that can act as oncogenes. Simple modifications of VICTR 20
would allow it to be used for these applications. For example, the
addition of an internal ribosome entry site (IRES) 3' to the
puromycin selectable marker and before the SD sequence, would
result in the overexpression of sequences from the trapped
downstream exons. In addition, the IRES could be modified by, for
example, the addition of one or two nucleotides such that there
could be 3 basic vectors that would allow expression of trapped
exons in all three reading frames. In this way, genes could be
trapped throughout the genome resulting in overexpression of genes,
or portions thereof, to examine the cellular function of the
trapped genes. This identification of function could be done by
selecting for the function of interest (i.e., growth in soft agar
could result from the overexpression of potentially oncogenic
genes). This technique would allow for the screening or selection
of large numbers of genes, or portions thereof, by overexpressing
the genes and identifying cells displaying the phenotypes of
interest. Additional assays could, for example, identify candidate
tumor suppressor genes based on their ability, when overexpressed,
to prevent growth in soft agar.
[0064] Given the fact that expression pattern information can
provide insight into the possible functions of genes mutated by the
current methods, another LTR vector, VICTR 6, has been constructed
in a manner similar to VICTR 5 except that the terminal exon has
been replaced with either a gene coding for .beta.-galactosidase
(.beta.gal) or a fusion between .beta.-gal and neomycin
phosphotransferase (.beta.geo), each proceeded by a splice acceptor
and followed by a polyadenylation signal. Endogenous gene
expression and splicing of these markers into cellular transcripts
and translation into fusion proteins will allow for increased
mutagenicity as well as the delineation of expression through Lac Z
staining.
[0065] An additional vector, VICTR 12, incorporates two separate
selectable markers for the analysis of both integration sites and
trapped genes. One selectable marker (e.g. puro) is similar to that
for VICTRs 3 through 5 in that it contains a promoter element at
its 5' end and a splice donor sequence 3'. This gene cassette is
located in the LTRs of the retroviral vector. The other marker
(neo) also contains a promoter element but has a polyadenylation
signal present at the 3' end of the coding sequence and is
positioned between the viral LTRs. Both selectable markers contain
an initiator ATG for proper translation. The design of VICTR 12
allows for the assessment of absolute titer as assayed by the
number of colonies resistant to antibiotic selection for the
constitutively expressed marker possessing a polyadenylation
signal. This titer can then be compared to that observed for
gene-trapping and stable expression of the resistance marker
flanked at its 3' end by a splice donor. These numbers are
important for the calculation of gene trapping frequency in the
context of both nonspecific binding by retroviral integrase and
directed binding by chimeric integrase fusions. In addition, it
provides an option to focus on the actual integration sites through
infection and selection for the marker containing the
polyadenylation signal. This eliminates the need for the fusion
protein binding to occur upstream and in the proximity of the
target gene. Theoretically, any transcription factor binding sites
present within the genome are targets for proximal integration and
subsequent antibiotic resistance. Analysis of sequences flanking
the LTRs of the retroviral vector should reveal canonical factor
binding sites. In addition, by including the promoter/splice donor
design of VICTR 3, gene-trapping abilities are retained in VICTR
12.
[0066] VICTR A is a vector which does not contain gene trapping
constructs but rather a selectable marker possessing all of the
required entities for constitutive expression including, but not
limited to, a promoter element capable of driving expression in
eukaryotic cells and a polyadenylation and transcriptional terminal
signal. Similar to VICTR 12, downstream gene trapping is not
necessary for successful selection using VICTR A. This vector is
intended solely to select for successful integrations and serves as
a control for the identification of transcription factor binding
sites flanking the integrant as mentioned above.
[0067] Finally, VICTR B is similar to VICTR A in that it comprises
a constitutively expressed selectable marker, but it also contains
the bacterial .beta.-lactamase ampicillin resistance selectable
marker and a ColEl origin of replication. These entities allow for
the rapid cloning of sequences flanking the long terminal repeats
through restriction digestion of genomic DNA from infected cells
and ligation to form plasmid molecules which can be rescued by
bacterial transformation, and subsequently sequenced. This vector
allows for the rapid analysis of cellular sequences that contain
putative binding sites for the transcription factor of
interest.
[0068] Other vector designs contemplated by the present invention
are engineered to include an inducible regulatory elements such as
tetracycline, ecdysone, and other steroid-responsive promoters (No
et al., Proc Natl Acad Sci USA 93:3345-51, 1996; Furth et al., Proc
Natl Acad Sci USA 91:9302-6, 1994). These elements are operatively
positioned to allow the inducible control of expression of either
the selectable marker or endogenous genes proximal to site of
integration. Such inducibility provides a unique tool for the
regulation of target gene expression.
[0069] All of the gene trap vectors of the VICTR series, with the
exception of VICTRs A and B, are designed to form a fusion
transcript between vector encoded sequence and the trapped target
gene. All of the flanking exons may be sequenced according to the
methods described in the following section. To facilitate
sequencing, specific sequences are engineered onto the ends of the
selectable marker (e.g., puromycin coding region). Examples of such
sequences include, but are not limited to unique sequences for
priming PCR, and sequences complementary to standard M13 sequencing
primers. Additionally, stop codons are added in all three reading
frames to ensure that no anomalous fusion proteins are produced.
All of the unique 3' primer sequences are immediately followed by a
synthetic 9 base pair splice donor sequence. This keeps the size of
the exon comprising the selectable marker at a minimum to ensure
proper splicing, and positions the amplification and sequencing
primers immediately adjacent to the flanking trapped exons to be
sequenced as part of the generation of the collection of cells
representing mutated transcription factor targets.
[0070] Since a cryptic splice donor sequence is found in the
inverted LTRs, this cryptic splice donor sequence has been removed
from the VICTR vectors by site specific mutagenesis. It was deemed
necessary to remove this splice donor so that it would not affect
trapping associated splicing events.
[0071] When any members of the VICTR series are packaged into
infectious virus, the direction of transcription of the selectable
marker is opposite to that of the direction of the normal
transcription of the retrovirus. The reason for this organization
is that the regulatory elements such as the polyadenylation signal,
the splice sites and the promoter elements found in the various
members of the VICTR series can interfere with the transcription of
the retroviral genome in the packaging cell line. This potential
interference may significantly reduce retroviral titers.
[0072] Although specific gene trapping vectors have been discussed
at length above, the invention is by no means to be limited to such
vectors. Several other types of vectors that may also be used to
incorporate relatively small engineered exons into a target cell
transcripts include, but are not limited to, adenoviral vectors,
adenoassociated virus vectors, SV40 based vectors, and papilloma
virus vectors. Additionally, DNA vectors may be directly
transferred into the target cells using any of a variety of
biochemical or physical means such as lipofection, chemical
transfection, retrotransposition, electroporation, and the
like.
[0073] Although, the use of specific selectable markers has been
disclosed and discussed herein, the present invention is in no way
limited to the specifically disclosed markers. Additional markers
(and associated antibiotics) that are suitable for either positive
or negative selection of eukaryotic cells are disclosed, inter
alia, in Sambrook et al. (1989) Molecular Cloning Vols. I-III, Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., and
Current Protocols in Molecular Biology (1989) John Wiley &
Sons, all Vols. and periodic updates thereof, as well as/Table I of
U.S. Pat. No. 5,464,764 issued Nov. 7, 1995, the entirety of which
is herein incorporated by reference. Any of the disclosed markers,
as well as others known in the art, may be used to practice the
present invention.
5.2. The Analysis of Mutated Genes and Transcripts
[0074] The presently described invention allows for large-scale
genetic analysis of the genomes of any organism for which there
exists cultured cell lines. The Library may be constructed from any
type of cell that can be transfected by standard techniques or
infected with recombinant retroviral vectors.
[0075] Where mouse ES cells are used, then the Library becomes a
genetic tool able to completely represent mutations in essentially
every gene of the mouse genome. Since ES cells can be injected back
into a blastocyst and become incorporated into normal development
and ultimately the germ line, the cells of the Library effectively
represent a complete panel of mutant transgenic mouse strains (see
generally, U.S. Pat. No. 5,464,764 issued Nov. 7, 1995, herein
incorporated by reference).
[0076] A similar methodology may be used to construct virtually any
non-human transgenic animal (or animal capable of being rendered
transgenic). Such nonhuman transgenic animals may include, for
example, transgenic pigs, transgenic rats, transgenic rabbits,
transgenic cattle, transgenic goats, and other transgenic animal
species, particularly mammalian species, known in the art.
Additionally, bovine, ovine, and porcine species, other members of
the rodent family, e.g. rat, as well as rabbit and guinea pig and
non-human primates, such as chimpanzee, may be used to practice the
present invention.
[0077] Transgenic animals produced using the presently described
library and/or vectors are useful for the study of basic biological
processes and diseases including, but not limited to, aging,
cancer, autoimmune disease, immune disorders, alopecia, glandular
disorders, inflammatory disorders, diabetes, arthritis, high blood
pressure, atherosclerosis, cardiovascular disease, pulmonary
disease, degenerative diseases of the neural or skeletal systems,
Alzheimer's disease, Parkinson's disease, asthma, developmental
disorders or abnormalities, infertility, epithelial ulcerations,
and microbial pathogenesis (a relatively comprehensive review of
such pathogens is provided, inter alia, in Mandell et al., 1990,
"Principles and Practice of Infectious Disease" 3rd. ed., Churchill
Livingstone Inc., New York, N.Y. 10036, herein incorporated by
reference). As such, the described animals and cells are
particularly useful for the practice of functional genomics.
[0078] 5.2.1. Constructing a Library of Individually Mutated Cell
Clones
[0079] The vectors described in the previous section were used to
infect (or transfect) cells in culture, for example, mouse
embryonic stem (ES) cells. Gene trap insertions were initially
identified by antibiotic resistance (e.g., puromycin). Individual
clones (colonies) were moved from a culture dish to individual
wells of a multi-welled tissue culture plate (e.g. one with 96
wells). From this platform, the clones were be duplicated for
storage and subsequent analysis. Each multi-well plate of clones
was then processed by molecular biological techniques described in
the following section in order to derive sequence of the gene that
has been mutated. This entire process is presented schematically in
FIG. 4 (described below).
[0080] 5.2.2. Identifying and Sequencing the Tagged Genes in the
Library.
[0081] The relevant nucleic acid (and derived amino acid sequence
information) will largely be obtained using PCR-based techniques
that rely on knowing part of the sequence of the fusion transcripts
(see generally, Frohman et al., 1988, Proc. Natl. Acad. Sci. U.S.A.
85(23):8998-9000, and U.S. Pat. Nos. 4,683,195 to Saiki et al., and
4,683,202 to Mullis, which are herein incorporated by reference).
Typically, such sequences are encoded by the foreign exon
containing the selectable marker. The procedure is represented
schematically in FIG. 2 (3' RACE). Although each step of the
procedure may be done manually, the procedure is also designed to
be carried out using robots that can deliver reagents to multi well
culture plates (e.g., but not limited to, 96-well plates).
[0082] The first step generates single stranded complementary DNA
which is used in the PCR amplification reaction (FIG. 2). The RNA
substrate for cDNA synthesis may either be total cellular RNA or an
mRNA fraction; preferably the latter. mRNA was isolated from cells
directly in the wells of the tissue culture dish. The cells were
lysed and mRNA was bound by the complementary binding of the
poly-adenylate tail to a poly-thymidine-associated solid matrix.
The bound mRNA was washed several times and the reagents for the
reverse transcription (RT) reaction were added. cDNA synthesis in
the RT reaction was initiated at random positions along the message
by the binding of a random sequence primer (RS). This RS primer has
approximately 6-9 random nucleotides at the 3' end to bind sites in
the mRNA to prime cDNA synthesis, and a 5' tail sequence of known
composition to act as an anchor for PCR amplification in the next
step. There is therefore no specificity for the trapped message in
the RT step. Alternatively, a poly-dT primer appended with the
specific sequences for the PCR may be used. Synthesis of the first
strand of the cDNA initiates at the end of each trapped gene. At
this point in the procedure, the bound mRNA may be stored (at
between about -70.degree. C. and about 4.degree. C.) and reused
multiple times. Such storage is a valuable feature where one
subsequently desires to analyze individual clones in more detail.
The bound mRNA may also be used to clone the entire transcript
using PCR-based protocols.
[0083] Specificity for the trapped, fusion transcript is introduced
in the next step, PCR amplification. The primers for this reaction
are complementary to the anchor sequence of the RS primer and to
the selectable marker. Double stranded fragments between a fixed
point in the selectable marker gene and various points downstream
in the appended transcript sequence are amplified. It is these
fragments which will become the substrates for the sequencing
reaction. The various end-points along the transcript sequence were
determined by the binding of the random primer during the RT
reaction. These PCR products were diluted into the sequencing
reaction mix, denatured and sequenced using a primer specific for
the splice donor sequences of the gene trap exon. Although,
standard radioactively labeled nucleotides may be used in the
sequencing reactions, sequences will typically be determined using
standard dye terminator sequencing in conjunction with automated
sequencers (e.g., ABI sequencers and the like).
[0084] Several fragments of various sizes may serve as substrates
for the sequencing reactions. This is not a problem since the
sequencing reaction proceeds from a fixed point as defined by a
specific primer sequence. Typically, approximately 200 nucleotides
of sequence were obtained for each trapped transcript. For the PCR
fragments that are shorter than this, the sequencing reaction
simply `falls off` the end. Sequences further 3' were then covered
by the longer fragments amplified during PCR. One problem is
presented by the anchor sequences `S` derived from the RS primer.
When these are encountered during the sequencing of smaller
fragments, they register as anomalous dye signals on the sequencing
gels. To circumvent this potential problem, a restriction enzyme
recognition site is included in the S sequence. Digestion of the
double stranded PCR products with this enzyme prior to sequencing
eliminates the heterologous S sequences.
[0085] 5.2.3. Identifying the Tagged Genes by Chromosomal
Location
[0086] Any individually tagged gene may also be identified by PCR
using chromosomal DNA as the template. To find an individual clone
of interest in the Library arrayed as described above, genomic DNA
is isolated from the pooled clones of ES cells as presented in FIG.
3. One primer for the PCR is anchored in the gene trap vector,
e.g., a puro exon-specific oligonucleotide. The other primer is
located in the genomic DNA of interest. This genomic DNA primer may
consist of either (1) DNA sequence that corresponds to the coding
region of the gene of interest, or (2) DNA sequence from the locus
of the gene of interest. In the first case, the only way that the
two primers used may be juxtaposed to give a positive PCR results
(e.g., the correct size double-stranded DNA product) is if the gene
trap vector has inserted into the gene of interest. Additionally,
degenerate primers may be used, to identify and isolate related
genes of interest. In the second case, the only way that the two
primers used may be juxtaposed to provide the desired PCR result is
if the gene trap vector has inserted into the region of interest
that contains the primer for the known marker.
[0087] For example, if one wishes to obtain ES cell clones from the
library that contain mutated genes located in a certain chromosomal
position, PCR primers are designed that correspond to the puro gene
(the puro-anchored primer) and a primer that corresponds to a
marker known to be located in the region of interest. Several
different combinations of marker primers and primers that are
located in the region of interest may also be used to obtain
optimum results. In this manner, the mutated genes are identified
by virtue of their location relative to sets of known markers.
Genes in a particular chromosomal region of interest could
therefore be identified. The marker primers could also be designed
correspond to sequences of known genes in order to screen for
mutations in particular genes by PCR on genomic DNA templates.
While this method is likely to be less informative than the RT-PCR
strategy described below, this technique would be useful as a
alternative strategy to identify mutations in known genes. In
addition, primers that correspond to sequence of known genes could
be used in PCR reactions with marker-specific primers in order to
identify ES cell clones that contain mutations in genes proximal to
the known genes. The sensitivity of detection is adequate to find
such events when positive clones are subsequently identified as
described below in the RT-PCR strategy.
[0088] 5.3. A Sequence Database Identifies Genes Mutated in the
Library.
[0089] Using the procedures described above, approximately 200 to
about 600 bases of sequence from the cellular exons appended to the
selectable marker exon (e.g., puro exon in VICTR vectors) may be
identified. These sequences provide a means to identify and
catalogue the genes mutated in each clone of the Library. Such a
database provides both an index for the presently disclosed
libraries, and a resource for discovering novel genes.
Alternatively, various comparisons can be made between the Library
database sequences and any other sequence database as would be
familiar to those practiced in the art.
[0090] The novel utility of the Library lies in the ability for a
person to search the Library database for a gene of interest based
upon some knowledge of the nucleic acid or amino acid sequence.
Once a sequence is identified, the specific clone in the Library
can be accessed and used to study gene function. This is
accomplished by studying the effects of the mutation both in vitro
and in vivo. For example, cell culture systems and animal models
(i.e., transgenic animals) may be directly generated from the cells
found in the Library as will be familiar to those practiced in the
art.
[0091] Additionally, the sequence information may be used to
generate a highly specific probe for isolating both genomic clones
from existing data bases, as well as a full length cDNA.
Additionally, the probe may be used to isolate the homologous gene
from sufficiently related species, including humans. Once isolated,
the gene may be over expressed, or used to generate a targeted
knock-out vector that may be used to generate cells and animals
that are homozygous for the mutation of interest. Such animals and
cells are deemed to be particularly useful as disease models (i.e.,
cancer, genetic abnormalities, AIDS, etc.), for developmental
study, to assay for toxin susceptibility or the efficacy of
therapeutic agents, and as hosts for gene delivery and therapy
experiments (e.g., experiments designed to correct a specific
genetic defect in vivo).
[0092] 5.4. Accessing Clones in the Library by a Pooling and
Screening Procedure.
[0093] An alternative method of accessing individual clones is by
searching the Library database for sequences in order to isolate a
clone of interest from pools of library clones. The Library may be
arrayed either as single clones, each with different insertions, or
as sets of pooled clones. That is, as many clones as will represent
insertions into essentially every gene in the genome are grown in
sets of a defined number. For example, 100,000 clones can be
arrayed in 2,000 sets of 50 clones. This can be accomplished by
titrating the number of VICTR retroviral particles added to each
well of 96-well tissue culture plates. Two thousand clones will fit
on approximately 20 such plates. The number of clones may be
dictated by the estimated number of genes in the genome of the
cells being used. For example, there are approximately 100,000
genes in the genome of mouse ES cells. Therefore, a Library of
mutations in essentially every gene in the mouse genome may be
arrayed onto 20 96-well plates.
[0094] To find an individual clone of interest in the Library
arrayed in this manner, reverse transcription-polymerase chain
reactions (RT-PCR) are performed on mRNA isolated from pooled
clones as presented in FIG. 4. One primer for RT-PCR is anchored in
the gene trap vector, i.e. a puro exon-specific oligonucleotide.
The other primer is located in the cDNA sequence of a gene of
interest. The only way that these two sequences can be juxtaposed
to give a positive RT-PCR result (i.e. double stranded DNA fragment
visible by agarose gel electrophoresis, as will be familiar to
anyone practiced in the art) is by being present in a transcript
from a gene trap event occurring in the gene of interest.
[0095] For example, if one wishes to obtain an ES cell clone with a
mutation in the p53 gene, PCR primers are designed that correspond
to the puro and p53 genes. If a VICTR trapping vector integrates
into the p53 locus and results in the formation of a fusion mRNA,
this mRNA may be detected by RT-PCR using these specifically
designed primer pairs. The sensitivity of detection is adequate to
find such an event when positive cells are mixed with a large
background of negative cells. The individual positive clones are
subsequently identified by first locating the pool of 50 clones in
which it resides. This process is described in FIG. 5. The positive
pool, once identified, is subsequently plated at limiting dilution
(approximately 0.3 cells/well) such that individual clones may be
isolated. To find the one positive event in 50 clones represented
by this pool, individual clones are isolated and arrayed on a
96-well plate. By pooling in columns and rows, the positive well
containing the positive clone can be identified with relatively few
RT-PCR reactions.
[0096] In addition to RT-PCR, the pools may be screened by
hybridization techniques (see generally Sambrook et al., 1989,
Molecular Cloning: H Laboratory Manual 2nd edition, Cold Spring
Harbor Press, Cold Spring Harbor, and Current Protocols in
Molecular Biology, 1995, Ausubel et al. eds., John Wiley and Sons).
Specific PCR fragments are generated from the mutated genes
essentially as described above for the sequencing protocols of the
individual clones (first-strand synthesis using RT primed by a
random or oligo dT primer that is appended to a specific primer
binding site). The gene trap DNA is amplified from the primer sets
in the puro gene and the specific sequences appended to the RT
primer. If this were done with pools, the resulting pooled set of
amplified DNA fragments could be arrayed on membranes and probed by
radioactive, or chemically or enzymatically labeled, hybridization
probes specific for a gene of interest. A positive radioactive
result indicates that the gene of interest has been mutated in one
of the clones of the positively-labeled pool. The individual
positive clone is subsequently identified by PCR or hybridization
essentially as outlined above.
[0097] Alternatively, a similar strategy may be used to identify
the clone of interest from multiple plates, or any scheme where a
two or three dimensional array (e.g., columns and rows) of
individual clones are pooled by row or by column. For example, 96
well plates of individual clones may be arranged adjacent to each
other to provide a larger (or virtual/figurative) two dimensional
grid (e.g., four plates may be arranged to provide a net
16.times.24 grid), and the various rows and columns of the larger
grid may be pooled to achieve substantially the same result.
[0098] Similarly, plates may simply be stacked, literally or
figuratively; or arranged into a larger grid and stacked to provide
three dimensional arrays of individual clones. Representative pools
from all three planes of the three dimensional grid may then be
analyzed, and the three positive pools/planes may be aligned to
identify the desired clone. For example, ten 96 well plates may be
screened by pooling the respective rows and columns from each plate
(a total of 20 pools) as well as pooling all of the clones on each
specific plate (10 additional pools). Using this method, one may
effectively screen 960 clones by performing PCR on only 30 pooled
samples.
[0099] The example provided below is merely illustrative of the
subject invention. Given the level of skill in the art, one may be
expected to modify any of the above or following disclosure to
produce insubstantial differences from the specifically described
features of the present invention. As such, the following example
is provided solely by way of illustration and is not included for
the purpose of limiting the invention in any way whatsoever.
6.0. EXAMPLES
[0100] 6.1. Use of VICTR Series Vectors to Construct a Mouse ES
cell Gene Trap Library
[0101] VICTR 3 was used to gather a set of gene trap clones. A
plasmid containing the VICTR 3 cassette was constructed by
conventional cloning techniques and designed to employ the features
described above. Namely, the cassette contained a PGK promoter
directing transcription of an exon that encodes the puro marker and
ends in a canonical splice donor sequence. At the end of the
puromycin exon, sequences were added as described that allow for
the annealing of two nested PCR and sequencing primers. The vector
backbone was based on pBluescript KS+ from Stratagene
Corporation.
[0102] The plasmid construct linearized by digestion with Sca I
which cuts at a unique site in the plasmid backbone. The plasmid
was then transfected into the mouse ES cell line AB2.2 by
electroporation using a BioRad Genepulser apparatus. After the
cells were allowed to recover, gene trap clones were selected by
adding puromycin to the medium at a final concentration of 3%
.mu.g/mL. Positive clones were allowed to grow under selection for
approximately 10 days before being removed and cultured separately
for storage and to determine the sequence of the disrupted
gene.
[0103] Total RNA was isolated from an aliquot of cells from each of
18 gene trap clones chosen for study. Five micrograms of this RNA
was used in a first strand cDNA synthesis reaction using the "RS"
primer. This primer has unique sequences (for subsequent PCR) on
its 5' end and nine random nucleotides or nine T (thymidine)
residues on it's 3' end. Reaction products from the first strand
synthesis were added directly to a PCR with outer primers specific
for the engineered sequences of puromycin and the "RS" primer.
After amplification, an aliquot of reaction products were subject
to a second round of amplification using primers internal, or
nested, relative to the first set of PCR primers. This second
amplification provided more reaction product for sequencing and
also provided increased specificity for the specifically gene
trapped DNA.
[0104] The products of the nested PCR were visualized by agarose
gel electrophoresis, and seventeen of the eighteen clones provided
at least one band that was visible on the gel with ethidium bromide
staining. Most gave only a single band which is an advantage in
that a single band is generally easier to sequence. The PCR
products were sequenced directly after excess PCR primers and
nucleotides were removed by filtration in a spin column
(Centricon-100, Amicon). DNA was added directly to dye terminator
sequencing reactions (purchased from ABI) using the standard M13
forward primer a region for which was built into the end of the
puro exon in all of the PCR fragments. Thirteen of the seventeen
clones that gave a band after the PCR provided readable
sequence.
[0105] The minimum number of readable nucleotides was 207 and some
of the clones provided over 500 nucleotides of useful sequence.
[0106] Sample data from this set of clones is presented in FIG. 6.
Only a portion of sequence (nucleotide or putative amino acid) for
9 Library clones obtained by the methods described in this
invention are presented. Under each sequence fragment in the figure
is aligned a homologous sequence that was identified using the
BLAST (basic local alignment search tool) search algorithm
(Altschul et al., 1990, J. Mol. Biol. 215:403-410).
[0107] In addition to known sequences, many new genes were also
identified. Each of these sequences is labeled "OST" for "Omnibank
Sequence Tags." OMNIBANK.TM. shall be the trademark name for the
Libraries generated using the disclosed technology.
[0108] These data demonstrate that the VICTR series vectors may
efficiently trap genes, and that the procedures used to obtain
sequence are reliable. With simple optimization of each step, it is
presently possible to mutate every gene in a given population of
cells, and obtain sequence from each of these mutated genes. The
sample data provided in this example represents a small fraction of
an entire Library. By simply performing the same procedures on a
larger scale (with automation) a Library may be constructed that
collectively comprises and indexes mutations in essentially every
gene in the genome of the target cell.
[0109] Additional studies have used both VICTR 3 and VICTR 20. Like
VICTR 3, VICTR 20 is exemplary of a family of vectors that
incorporate two main functional units: a sequence acquisition
component having a strong promoter element (phosphoglycerate kinase
1) active in ES cells that is fused to the puromycin resistance
gene coding sequence which lacks a polyadenylation sequence but is
followed by a synthetic consensus splice donor sequence
(PGKpuroSD); and 2) a mutagenic component that incorporates a
splice acceptor sequence fused to a selectable, calorimetric marker
gene and followed by a polyadenylation sequence (for example,
SA.beta.geopA or SAIRES.beta.geopA). Also like VICTR 3, stop codons
have been engineered into all three reading frames in the region
between the 3' end of the selectable marker and the splice donor
site. A diagrammatic description of structure and functions of
VICTRs 3 and 20 is provided in FIG. 7.
[0110] When VICTRs 3 and 20 were used in the commercial scale
application of the presently disclosed invention, over 3,000
mutagenized ES cell clones were rapidly engineered and obtained.
Sequence analysis obtained from these clones has identified a wide
variety of both previously identified and novel sequences. A
representative sampling of previously known genes that were
identified using the presently described methods is provided in
FIG. 8. The power of the presently described invention as a
genomics resource becomes apparent when one considers that the
genes listed in FIG. 8 were obtained and identified in less than a
year whereas the references associated with the identification of
the known genes span a period of roughly two decades. More
importantly, the majority of the sequences thus far identified are
novel, and, because of the functional aspects of the presently
described ES cell system, the cellular and developmental functions
of these novel sequences can be rapidly established.
7.0. REFERENCE TO MICROORGANISM DEPOSITS
[0111] The following plasmids have been deposited at the American
Type Culture Collection (ATCC), Rockville, Md., USA, under the
terms of the Budapest Treaty on the International Recognition of
the Deposit of Microorganisms for the Purposes of Patent Procedure
and Regulations thereunder (Budapest Treaty) and are thus
maintained and made available according to the terms of the
Budapest Treaty. Availability of such plasmids is not to be
construed as a license to practice the invention in contravention
of the rights granted under the authority of any government in
accordance with its patent laws.
[0112] The deposited cultures have been assigned the indicated ATCC
deposit numbers:
TABLE-US-00001 Plasmid ATCC No. plex 97748 pExonII 97749 ppuro7
97750 ppuro5 97751 ppuro11 97752 ppuro10 97753
[0113] All publications and patents mentioned in the above
specification are herein incorporated by reference. Various
modifications and variations of the described method and system of
the invention will be apparent to those skilled in the art without
departing from the scope and spirit of the invention. Although the
invention has been described in connection with specific preferred
embodiments, it should be understood that the invention as claimed
should not be unduly limited to such specific embodiments. Indeed,
various modifications of the above-described modes for carrying out
the invention which are obvious to those skilled in the field of
molecular biology or related fields are intended to be within the
scope of the following claims.
Sequence CWU 1
1
18155DNAMus musculus 1tttatataat atttaatttg ttttactggg gtatatatgt
gtgaagagga cttct 55255DNARattus norvegicus 2tttacataat atttaatttg
ttttactggg gtatatatgt gtgaagagga ctttt 55360DNAMus
musculusmisc_feature(49)..(49)n is A, C, G, or T 3accgttgcgg
aggctcacgt ttctcagata gtacatcagg tgtcatcgnt gtcagaaggt 60460DNAMus
musculus 4accgttgcgg ggcctcacgt ttctcagata gtacatcagg tgtcatcgtt
atcagaaagt 60560PRTMus musculusMISC_FEATURE(22)..(22)Xaa is an
unknown amino acid 5Gly Ile Gly Met His His Ala Gly Leu His Glu Arg
Asp Arg Lys Thr1 5 10 15Val Glu Glu Leu Phe Xaa Asn Cys Lys Val Gln
Val Leu Ile Ala Thr20 25 30Ser Thr Leu Ala Trp Gly Val Asn Phe Pro
Ala His Leu Val Ile Ile35 40 45Lys Gly Thr Glu Tyr Tyr Asp Gly Lys
Thr Arg Arg50 55 60660PRTSaccharomyces cerevisiae 6Gly Ile Gly Leu
His His Ala Gly Leu Val Gln Lys Asp Arg Ser Ile1 5 10 15Ser His Gln
Leu Phe Gln Lys Asn Lys Ile Gln Ile Leu Ile Ala Thr20 25 30Ser Thr
Leu Ala Trp Gly Val Asn Leu Pro Ala His Leu Val Ile Ile35 40 45Lys
Gly Thr Gln Phe Phe Asp Ala Lys Ile Glu Gly50 55 60760DNAMus
musculusmisc_feature(14)..(14)n is A, C, G, or T 7gcgcagaagt
ggtnctggaa ntttntccgc cnccatccag tctattaatt gttgacngga
60860DNAUnknownsequence from US patent 5470724 8gcgcagaagt
ggtcctgcaa ctttatccgc ctccatccag tctattaatt gttgccggga 60923PRTMus
musculusMISC_FEATURE(10)..(10)Xaa is an unknown amino acid 9Thr Cys
Trp Ile Arg Leu Gly Thr Arg Xaa Val Gly Ala Ser Leu Glu1 5 10 15Tyr
Glu Tyr Ile Arg Ala Ser201024PRTMus musculus 10Thr Cys Trp Leu Gln
Leu Ala Asp Phe Arg Lys Val Gly Asp Ala Leu1 5 10 15Lys Glu Lys Tyr
Asp Ser Ala Ala201160DNAMus musculus 11cttatatggc tacggcggct
tcaacatctc cattacaccc aactacagcg tgtccaggct 601260DNAHomo sapiens
12cttatatggc tatggcggct tcaacatatc catcacaccc aactacagtg tttccaggct
601360DNAMus musculus 13aaagcatgta gcagttgtag gacacactag acgagagcac
cagatctcat tgtgggtggt 601460DNAMus musculus 14aaagcatgta gcagttgtag
gacacactag acgagagcac cagatctcat tgtgggtggt 601560DNAMus
musculusmisc_feature(10)..(10)n is A, C, G, or T 15tggatgcagn
ctaccactgt gtggctgccc tattttacct cagtgcctca gttctggaag
601660DNARattus norvegicus 16tggatgcagc ctaccactgt gtggctgccc
tgttttacct cagtgcctca gtcctggaag 601760DNAMus musculus 17acctgattgt
tatccgtggc ctgcagaagt ccagaaaata cagaccaaag tcaaccagta 601860DNAMus
musculus 18acctgattgt tatccgtggc ctgcagaagt ccagaaaata cagaccaaag
tcaaccagta 60
* * * * *